China Health Group Inc
China Health Group Inc provides healthcare diagnostics services and related products, primarily operating in the biotechnology and medical research sector.
Business. China Health Group Inc (8225.HK) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
China Health Group Inc (8225.HK) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
China Health Group Inc has a market capitalization of 123,423,605.84 CNY, with a market price of 0.124 CNY per share. The company has 995,351,660 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company reported a last actual EPS of 0.01 CNY and revenue of 40,519,000 CNY, suggesting limited profitability. These figures are below the typical thresholds for robust performance in the Life Sciences Tools & Services industry, which is part of the broader Health Care sector. The company's financials indicate a need for improvement in both revenue generation and profitability to align with industry standards.
China Health Group Inc operates primarily in the healthcare diagnostics segment, with a focus on biotechnology and medical research. The company's revenue concentration is not disclosed, but the lack of segment-specific data suggests a potential overreliance on a single business line or geographic region.
The company's growth trajectory is uncertain, as no specific revenue growth rates or future projections are provided. The absence of detailed financial history and forward-looking guidance makes it difficult to assess the company's potential for expansion or contraction in the coming fiscal years.
The risk assessment indicates low dilution potential, but the company faces significant liquidity risk due to the lack of balance-sheet data and no going-concern language in source documents. This uncertainty could impact the company's ability to meet short-term obligations and may affect investor confidence.
Recent events and filings do not provide additional insights into the company's operations or strategic direction. The absence of detailed transcripts or recent filings suggests a lack of transparency and may raise concerns about the company's governance and operational health.
- China Health Group Inc has a low market price and market capitalization, indicating limited investor interest.
- The company's financial performance is weak, with a low EPS and revenue, suggesting a need for improvement in profitability.
- The company's liquidity risk is unassessable due to the lack of balance-sheet data and no going-concern language.
- The company's growth trajectory is uncertain, with no clear guidance on future revenue or expansion plans.
- The company's risk profile is characterized by low dilution potential but high liquidity risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥28.6M, +8,0% YoY; Operating income −3,4% YoY.
- ▍Revenue ¥28.6M, +8,0% YoY
- ▍Operating income −3,4% YoY
- ▍Net income −3,0% YoY
- ▍Net margin -52.4%
Revenue ¥26.5M, +23,5% YoY; Operating income +75,1% YoY.
- ▍Revenue ¥26.5M, +23,5% YoY
- ▍Operating income +75,1% YoY
- ▍Net income +75,1% YoY
- ▍Free cash flow +75,1% YoY
- ▍Net margin -54.9%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- China Health Group Inc Market data — financials · 2026-05-27
- China Health Group Inc Market data — analyst estimates · 2026-05-27